Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 10/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 4/20 | 0.46 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP7 | P09237 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 3/20 | 0.45 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30921215 | 0.82 | ABCB1 (0.43) | MMP13 | |
| SCHEMBL12446946 | 0.81 | ABCB1 (0.42) | MMP13 | |
| SCHEMBL845706 | 0.80 | GPR119 (0.47) | GPR119MMP13STSMMP1MMP3 | |
| SCHEMBL859745 | 0.80 | GPR119 (0.47) | GPR119MMP13STSMMP1MMP3 | |
| SCHEMBL7921618 | 0.78 | USP30 (0.49) | GPR119STSTGFBR1 | |
| SCHEMBL5767890 | 0.76 | ABCB1 (0.39) | MMP13 | |
| SCHEMBL14432139 | 0.75 | GPR119 (0.46) | GPR119MMP13STSMMP1KDM4E | |
| SCHEMBL1155839 | 0.74 | GPR119 (0.54) | GPR119MMP13STSMMP1KDM4E | |
| SCHEMBL968159 | 0.74 | GPR119 (0.54) | GPR119MMP13STSMMP1KDM4E | |
| SCHEMBL1155840 | 0.74 | GPR119 (0.54) | GPR119MMP13STSMMP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1687296-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049602-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | GPR119 2776/4885MMP13 2284/4885STS 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.